Results 171 to 180 of about 27,972 (180)
Some of the next articles are maybe not open access.
Human medicines European public assessment report (EPAR): Sprycel, dasatinib, Precursor Cell Lymphoblastic Leukemia-Lymphoma,Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Date of authorisation: 20/11/2006, Revision: 32, Status: Authorised
Case Medical Research, 2019 openaire +2 more sourcesHuman medicines European public assessment report (EPAR): Jylamvo, methotrexate, Arthritis, Psoriatic,Precursor Cell Lymphoblastic Leukemia-Lymphoma,Psoriasis,Arthritis, Rheumatoid,Arthritis, Date of authorisation: 29/03/2017, Revision: 4, Status: Authorised
Case Medical Research, 2019 openaire +1 more sourceHuman medicines European public assessment report (EPAR): Jylamvo, methotrexate, Arthritis, Psoriatic,Precursor Cell Lymphoblastic Leukemia-Lymphoma,Psoriasis,Arthritis, Rheumatoid,Arthritis, Date of authorisation: 29/03/2017, Revision: 2, Status: Authorised
Case Medical Research, 2019 openaire +1 more sourceHuman medicines European public assessment report (EPAR): Imatinib Actavis, imatinib, Leukemia, Myelogenous, Chronic, BCR-ABL Positive,Precursor Cell Lymphoblastic Leukemia-Lymphoma,Myelodysplastic-Myeloproliferative Diseases,Hypereosinophilic Syndrome,Dermatofibrosarcoma, Date of authorisation: 17/04/2013, Revision: 12, Status: Authorised
Case Medical Research, 2019 openaire +1 more source